Mefloquine artemisinin potentiates

There are two reasons for the great interest being shown in artemisinin and its derivatives. First, there is little cross resistance with Plasmodium falciparum between the members of this series and the quinoline-based antimalarials like chloroquine (203). On the contrary, significant potentiation of effect is observed in combination with chloroquine analogs such as mefloquine (204). Second, the high lipid solubility of, for example, arte-mether ensures rapid penetration into the CNS, so these sesquiterpene lactones are first-... 

Among potential malarial treatments attributable to the program are 1) mefloquine, 2) halofantrine, 3) artemisinin, and 4) a compound currently known as WR238605. Mefloguine was developed jointly by Walter Reed, WHO, and Hoffman-LaRoche, Inc., and was recently approved for U.S. marketing by the U.S. Food and Drug Administration (FDA). Halofantrine is a potential prophylactic jointly developed by Walter Reed and SmithKline Beecham that may be effective... 

---